{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:01:57Z","timestamp":1785726117364,"version":"3.56.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Niemann-Pick disease type B (NPD-B) is a rare lysosomal storage disorder characterized by residual activity of acid sphingomyelinase (ASM). While functional inhibitors of ASM (FIASMAs) are widely prescribed as psychotropic medications, they may pose a particular risk to patients with NPD-B by further reducing the already impaired enzymatic function. Here, we report the case of a 20-year-old male with genetically confirmed NPD-B who experienced rapid clinical deterioration following the administration of zuclopenthixol, a drug not previously associated with FIASMA activity. Within 48\u2009hours of treatment initiation, the patient developed profound lethargy and markedly elevated creatine kinase (CK) levels of up to 22,000\u2009U\/L, consistent with rhabdomyolysis. Symptoms resolved quickly after discontinuation of zuclopenthixol. In vitro experiments using a radioactive [\n                    <jats:sup>1 4<\/jats:sup>\n                    C]-sphingomyelin assay in Jurkat cells demonstrated that zuclopenthixol dose-dependently inhibited ASM activity by up to 71.5%. Zuclopenthixol had not previously been recognized as a FIASMA and might therefore have been considered a rational choice for treating patients with NPD-B. Our findings challenge this assumption by identifying zuclopenthixol as a potent inhibitor of ASM activity. This novel insight is of high clinical relevance, given the frequent use of antipsychotics in the management of neuropsychiatric symptoms in lysosomal storage disorders. We propose that zuclopenthixol and other potential FIASMAs be carefully re-evaluated for use in this vulnerable patient population.\n                  <\/jats:p>","DOI":"10.1186\/s13023-026-04238-0","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T08:15:39Z","timestamp":1775722539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Zuclopenthixol inhibits residual activity of acid sphingomyelinase in Niemann pick disease type B: a case report with in vitro validation"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2848-8557","authenticated-orcid":false,"given":"Maximilian","family":"Schiller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina Marie","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Gulbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Scherbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"4","key":"4238_CR1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00408-016-9893-0","volume":"194","author":"von Ranke Fm","year":"2016","unstructured":"von Ranke FM, Pereira Freitas HM, Man\u00e7ano, Rodrigues RS, Hochhegger B, Escuissato D, et al. Pulmonary involvement in Niemann-Pick disease: a state-of-the-art review. Lung. 2016;194(4):511\u201318.","journal-title":"Lung"},{"issue":"1","key":"4238_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/gte.1997.1.13","volume":"1","author":"EH Schuchman","year":"1997","unstructured":"Schuchman EH, Miranda SR. Niemann-Pick disease: mutation update, genotype\/phenotype correlations, and prospects for genetic testing. Genet Test. 1997;1(1):13\u201319.","journal-title":"Genet Test"},{"issue":"9","key":"4238_CR3","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1002\/j.1460-2075.1989.tb08382.x","volume":"8","author":"LE Quintern","year":"1989","unstructured":"Quintern LE, Schuchman EH, Levran O, Suchi M, Ferlinz K, Reinke H, et al. Isolation of cDNA clones encoding human acid sphingomyelinase: occurrence of alternatively processed transcripts. Embo J. 1989;8(9):2469\u201373.","journal-title":"Embo J"},{"issue":"1\u20133","key":"4238_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.bbalip.2004.08.014","volume":"1685","author":"SL Sturley","year":"2004","unstructured":"Sturley SL, Patterson MC, Balch W, Liscum L. The pathophysiology and mechanisms of NP-C disease. Biochim Biophys Acta. 2004;1685(1\u20133):83\u201387.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"4238_CR5","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1212\/01.wnl.0000194208.08904.0c","volume":"66","author":"MM McGovern","year":"2006","unstructured":"McGovern MM, Aron A, Brodie SE, Desnick RJ, Wasserstein MP. Natural history of type a Niemann-Pick disease: possible endpoints for therapeutic trials. Neurology. 2006;66(2):228\u201332.","journal-title":"Neurology"},{"issue":"3","key":"4238_CR6","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/ng0795-288","volume":"10","author":"K Horinouchi","year":"1995","unstructured":"Horinouchi K, Erlich S, Perl DP, Ferlinz K, Bisgaier CL, Sandhoff K, et al. Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat Genet. 1995;10(3):288\u201393.","journal-title":"Nat Genet"},{"issue":"4","key":"4238_CR7","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/cge.12076","volume":"84","author":"P Irun","year":"2013","unstructured":"Irun P, Mall\u00e9n M, Dominguez C, Rodriguez-Sureda V, Alvarez-Sala LA, Arslan N, et al. Identification of seven novel SMPD1 mutations causing Niemann-Pick disease types A and B. Clin Genet. 2013;84(4):356\u201361.","journal-title":"Clin Genet"},{"issue":"8","key":"4238_CR8","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/gim.2013.4","volume":"15","author":"MM McGovern","year":"2013","unstructured":"McGovern MM, Lippa N, Bagiella E, Schuchman EH, Desnick RJ, Wasserstein MP. Morbidity and mortality in type B Niemann-Pick disease. Genet Med. 2013;15(8):618\u201323.","journal-title":"Genet Med"},{"key":"4238_CR9","doi-asserted-by":"crossref","unstructured":"Wasserstein MP, Desnick RJ, Schuchman EH, Hossain S, Wallenstein S, Lamm C, et al. The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal study. Pediatrics. 2004;114(6):e672\u20137.","DOI":"10.1542\/peds.2004-0887"},{"issue":"1","key":"4238_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000315101","volume":"26","author":"J Kornhuber","year":"2010","unstructured":"Kornhuber J, Tripal P, Reichel M, Muhle C, Rhein C, Muehlbacher M, et al. Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem. 2010;26(1):9\u201320.","journal-title":"Cell Physiol Biochem"},{"key":"4238_CR11","doi-asserted-by":"crossref","unstructured":"Kornhuber J, Muehlbacher M, Trapp S, Pechmann S, Friedl A, Reichel M, et al. Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One. 2011;6(8):e23852.","DOI":"10.1371\/journal.pone.0023852"},{"key":"4238_CR12","doi-asserted-by":"crossref","unstructured":"Gassert E, Avota E, Harms H, Krohne G, Gulbins E, Schneider-Schaulies S. Induction of membrane ceramides: a novel strategy to interfere with T lymphocyte cytoskeletal reorganisation in viral immunosuppression. PLoS Pathog. 2009;5(10):e1000623.","DOI":"10.1371\/journal.ppat.1000623"},{"issue":"12","key":"4238_CR13","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1056\/NEJMra2404606","volume":"391","author":"EFM Wijdicks","year":"2024","unstructured":"Wijdicks EFM, Ropper AH. Neuroleptic Malignant Syndrome. N Engl J Med. 2024;391(12):1130\u201338.","journal-title":"N Engl J Med"},{"key":"4238_CR14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.2147\/NDT.S45084","volume":"9","author":"K Nisijima","year":"2013","unstructured":"Nisijima K, Shioda K. Temporal changes in serum creatine kinase concentration and degree of muscle rigidity in 24 patients with neuroleptic malignant syndrome. Neuropsychiatr Dis Treat. 2013;9:853\u201359.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"4238_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1515\/hsz-2019-0270","volume":"401","author":"B Breiden","year":"2019","unstructured":"Breiden B, Sandhoff K. Emerging mechanisms of drug-induced phospholipidosis. Biol Chem. 2019;401(1):31\u201346.","journal-title":"Biol Chem"},{"issue":"2","key":"4238_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1021\/jm070524a","volume":"51","author":"J Kornhuber","year":"2008","unstructured":"Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, et al. Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J Med Chem. 2008;51(2):219\u201337.","journal-title":"J Med Chem"},{"issue":"1","key":"4238_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00213-002-1059-5","volume":"162","author":"P Jaanson","year":"2002","unstructured":"Jaanson P, Marandi T, Kiivet RA, Vasar V, V\u00e4\u00e4n S, Svensson JO, et al. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacol (Berl). 2002;162(1):67\u201373.","journal-title":"Psychopharmacol (Berl)"},{"issue":"8","key":"4238_CR18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00249-008-0338-4","volume":"37","author":"S Trapp","year":"2008","unstructured":"Trapp S, Rosania GR, Horobin RW, Kornhuber J. Quantitative modeling of selective lysosomal targeting for drug design. Eur Biophys J. 2008;37(8):1317\u201328.","journal-title":"Eur Biophys J"},{"issue":"1","key":"4238_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1600-0447.1991.tb01428.x","volume":"84","author":"ML Dahl","year":"1991","unstructured":"Dahl ML, Ekqvist B, Wid\u00e9n J, Bertilsson L. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand. 1991;84(1):99\u2013102.","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"4238_CR20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0009-9236(96)90111-3","volume":"59","author":"M Jerling","year":"1996","unstructured":"Jerling M, Dahl ML, Aberg-Wistedt A, Liljenberg B, Landell NE, Bertilsson L, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther. 1996;59(4):423\u201328.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"4238_CR21","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/nm.3214","volume":"19","author":"E Gulbins","year":"2013","unstructured":"Gulbins E, Palmada M, Reichel M, Luth A, Bohmer C, Amato D, et al. Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. Nat Med. 2013;19(7):934\u201338.","journal-title":"Nat Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04238-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04238-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04238-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:40:09Z","timestamp":1781646009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04238-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4238"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04238-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to local institutional policy and national regulations, retrospective single-patient case reports based on fully anonymized clinical data do not require formal approval by an ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent for publication of anonymised clinical data was obtained from the patient\u2019s legal guardian.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}